ArticleNutrients2020
Efficacy of a Novel ACE-Inhibitory Peptide from
Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Food-Derived Multi-Target Antihypertensive Peptides: Sources, Mechanisms and AI-Driven Strategies.Foods (Basel, Switzerland) · 2026Review
- Isolation, Purification, Identification, and In Vitro ACE Inhibitory Activity of Tyrosine-Arginine Dipeptide From Red Millet Huangjiu.Food science & nutrition · 2026Article
- Influence ofAntioxidants (Basel, Switzerland) · 2026Article
- Article
- Marine Bioactive Peptides in the Regulation of Inflammatory Responses: Current Trends and Future Directions.Proteomes · 2025Review
- Therapeutic and Nutraceutical Potential ofMarine drugs · 2025Review
- Multifaceted Marine Peptides and Their Therapeutic Potential.Marine drugs · 2025Review
- Seaweed Proteins: Properties, Extraction, Challenges, and Prospects.Journal of food science · 2025Review
- Bioactive Compounds of Marine Algae and Their Potential Health and Nutraceutical Applications: A Review.Marine drugs · 2025Review
- Article
- From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides-Mechanisms and Applications.Marine drugs · 2024Review
- Identification and Characterization of Novel ACE Inhibitory and Antioxidant Peptides fromFoods (Basel, Switzerland) · 2023Article
- Potential Active Marine Peptides as Anti-Aging Drugs or Drug Candidates.Marine drugs · 2023Review
- Macroalgal Proteins: A Review.Foods (Basel, Switzerland) · 2022Review
- Seaweed-Derived Proteins and Peptides: Promising Marine Bioactives.Antioxidants (Basel, Switzerland) · 2022Review
- Seaweed Protein Hydrolysates and Bioactive Peptides: Extraction, Purification, and Applications.Marine drugs · 2021Review
- Identification, Characterization and Antihypertensive Effect In Vivo of a Novel ACE-Inhibitory Heptapeptide from Defatted Areca Nut Kernel Globulin Hydrolysates.Molecules (Basel, Switzerland) · 2021Article
- Two novel potent ACEI peptides isolated fromRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Sargassum maclurei is a potential protein resource because of its high protein content and relatively balanced amino acid composition. To promote its usage in food, medical, or other industries, S. maclurei protein was hydrolyzed by pepsin and papain to obtain bioactive peptides. The S. maclurei protein hydrolysates (SMPHs) were purified using gel chromatography and reversed-phase high performance liquid chromatography (RP-HPLC), and 12 major fractions were obtained. The fraction D11 with the highest angiotensin I-converting enzyme (ACE) inhibition (61.59%, at 1 mg/ mL) was subjected to liquid chromatography-mass spectrometry (LC-MS/MS) analysis, and about 17 peptides were identified, of which the RWDISQPY (1063.5 Da) was chosen to be synthesized based on in silico analysis. The RWDISQPY demonstrated high ACE inhibition ability (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.